Agios signs US$147.5 M License Deal with Alnylam’s RNAi therapeutic for Polycythemia Vera

By Shweta Gupta

Pharma Deals Review: Vol 2023 Issue 8 (Table of Contents)

Published: 22 Aug-2023

DOI: 10.3833/pdr.v2023.i8.2801     ISSN: 1756-7874

Section: Licensing



In a bid to bolster its rare disease portfolio, Agios Pharmaceuticals has entered into an exclusive worldwide license agreement with Alnylam Pharmaceuticals for the development and commercialisation of RNA interference (siRNA) therapeutics for the treatment of the rare haematologic disease, polycythemia vera (PV)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details